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Reply from the Authors
We thank Szczech and Winston for their interest in our
study and would like to clarify certain points. We con-
cede to the possible biases recounted; however, the intent
of our study was to evaluate the effect of angiotensin-
converting enzyme inhibition (ACEI), not antiretrovi-
ral therapy (ARV) or highly active antiretrovrial therapy
(HAART), on long-term renal survival in HIVAN. The
survival benefit of ARV, and even more so of HAART, in
human immunodeficiency virus infection is clear, but the
effects on renal survival have yet to be established. In fact,
in the referenced study by Szczech et al of more than 2000
HIV infected women, ARV monotherapy, ARV combi-
nation therapy, and HAART, all failed to affect the risk
of renal failure [1]. This was also true when those with
proteinuria were analyzed separately. In the article by
Laradi et al referenced by Szczech and Winston, history
of antiretroviral use was actually associated with worse
patient survival, making conclusions regarding the effects
of antiretrovirals on renal survival unattainable.
Higher initial CD4 counts have consistently been
shown in numerous studies, including our own, to be an
independent variable associated with better renal out-
comes. However, it does not necessarily follow that in
HIVAN decreasing the HIV viral load or increasing the
CD4 lymphocyte count will improve renal survival. This
has been suggested by case reports [3, 4], but the issue
needs to be addressed in larger prospective studies. While
we prefer not to speculate on the role of ARV or HAART
as a specific therapy for HIVAN, the authors would like
to stress the importance of early diagnosis and interven-
tion in HIVAN. There is compelling evidence that early
initiation of ACE-I improves long-term renal survival in
HIVAN.
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Home nocturnal hemodialysis
To the Editor: Home nocturnal hemodialysis (HND)
has been an established form of treatment on a world-
wide basis since its introduction in 1964 [1–4]. In its early
days, many thought that it was superior to transplantation
and was more cost effective than in center dialysis. Alas,
the passage of time has not confirmed any of these ear-
lier hopes. It is rarely practiced today for many reasons,
including the increasing age and comorbidity of the end-
stage renal population being maintained on hemodialysis,
although I still have one patient who has performed HND
4 times a week for 33 years [5]. Unless the increase in fre-
quency of HND to 5 to 7 times per week can really be
shown to be applicable on a large scale in less than highly
motivated patients and staff, I doubt that the aspirations
and claims of McFarlane et al [6] will stand the test of time
more than our hopes and aspirations of 40 years ago.
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Reply from the Authors
We agree with Dr. Shaldon that long intermittent
hemodialysis at home did not gain popularity in early
days. However, we are more optimistic than Dr. Shaldon
when considering more recent experiences [1]. The use
of quotidian nocturnal hemodialysis is increasing. In
Canada, the last few years have seen the start of at least
four new home nocturnal hemodialysis programs, and the
number of patients on the modality has doubled to more
than 150. A similar number of patients are on nocturnal
hemodialysis in the United States, and other programs
exist in The Netherlands [2], Sweden [3], Germany, and
Australia [4]. Furthermore, there are more than 300 pa-
tients primarily in the United States who are on long
